Topics

Molecular Partners AG: Molecular Partners Announces First Patient Dosed in Phase 1 Trial of MP0310, a Novel Tumor-Localized Immunotherapy

01:08 EDT 3 Oct 2019 | FinanzNachrichten

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 3, 2019 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*...

Original Article: Molecular Partners AG: Molecular Partners Announces First Patient Dosed in Phase 1 Trial of MP0310, a Novel Tumor-Localized Immunotherapy

NEXT ARTICLE

More From BioPortfolio on "Molecular Partners AG: Molecular Partners Announces First Patient Dosed in Phase 1 Trial of MP0310, a Novel Tumor-Localized Immunotherapy"

Quick Search

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...